CRISM Therapeutics Corporation CRTX

LSE · United Kingdom · Commercial Services

GBp 9.500.00 (0.00%)

Market closed· Oct 1, 2026, 9:37 AM UTC· GBp · Data may be delayed

Prices may be delayed and are for informational purposes only - not investment advice.

CRISM Therapeutics Corporation CRTX

LSE · United Kingdom · Commercial Services

GBp 9.500.00 (0.00%)

Market closed· Oct 1, 2026, 9:37 AM UTC· GBp · Data may be delayed

Prices may be delayed and are for informational purposes only - not investment advice.

-19.15% · 6MFull-screen chart

Open GBp 0.00High GBp 9.50Low GBp 9.50Close GBp 9.50Volume 301

Oct 1, 2026

Charts by TradingView Lightweight Charts

Key statistics

Previous close: GBp 9.50
Volume: 301
Market cap: £7.52M
Avg. volume (1Y): 223.57K

Performance

1 week

-2.56%

1 month

-15.56%

3 months

0.00%

6 months

-13.64%

Year to date

-5.00%

1 year

-13.64%

Total return, dividends included.

Company profile

Sector: Commercial Services
Industry: Miscellaneous Commercial Services
Country: United Kingdom
Exchange: LSE
Shares outstanding: 79.19M
ISIN: VGG042401262
Beta: 1.25

Technical view

Below averages

Where the price sits against its 50- and 200-day moving averages.

Valuation & analysis

Makkler Fair Value, financial health score, analyst view, peers and MakklerAI.

News

Yahoo FinanceMar 17, 2026

CRISM Therapeutics shares jump 12% after FDA grants orphan drug status for brain cancer treatment

Shares in CRISM Therapeutics (AIM: CRTX) rose 12% to 13.4p on Tuesday after the clinical-stage drug delivery company announced the U.S. Food and Drug Administration has granted Orphan Drug Designation to its irinotecan-ChemoSeed programme for the treatment of malignant glioma. The designation...

Recent third-party headlines about this company, kept separate from Makkler's own editorial coverage and linking out to the publisher. Accuracy is the publisher's responsibility.